公开(公告)号：EP2344446A1

公开(公告)日：2011-07-20

申请号：EP09820117.1

申请日：2009-10-16

申请人： Akaal Pharma Pty Ltd

发明人： GROBELNY, Damian, W. ,  GILL, Gurmit, S.

IPC分类号： C07C215/68 ,  C07C215/10 ,  C07D209/38 ,  A61K31/136 ,  C07C215/18 ,  C07D209/44 ,  A61K31/137 ,  C07C215/52 ,  C07D215/06 ,  A61K31/4045 ,  C07C217/60 ,  C07D215/20 ,  A61K31/4245 ,  C07C217/62 ,  C07D217/04 ,  A61K31/47 ,  C07C217/80 ,  C07D223/16 ,  A61K31/551 ,  C07C225/16

CPC分类号： C07D209/08 ,  C07C215/18 ,  C07C217/72 ,  C07C225/16 ,  C07C311/16 ,  C07C2603/70 ,  C07C2603/74 ,  C07D209/12 ,  C07D209/38 ,  C07D209/44 ,  C07D215/06 ,  C07D215/20 ,  C07D217/04 ,  C07D223/16 ,  C07D405/12 ,  C07D413/10 ,  C07D413/14

摘要： The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.